Checkpoint inhibitor monotherapy in potentially study-eligible or non-study-eligible NSCLC patients in the German CRISP Registry real-world cohort (AIO-TRK-0315).

18. Oktober 2021

Griesinger F., Sebastian M., Brückl W., Hummel H.-D., Jaeschke B., Kern J., Schumann C., Wesseler C., Jänicke M., Fleitz A., Zacharias S., Hipper A., Groth A., Weichert W., Dörfel S., Petersen V., Schröder J., Wilke J., Eberhardt W.E.E., Thomas M., CRISP Register Gruppe, 2021.

Oncol Res Treat 2021;44(suppl 4):1–329 p. 111

Download